CTOs on the Move

CodeSignal

www.codesignal.com

 
Founded in 2015, CodeSignal is the first company to develop an objective automated skills-based assessment platform that can be used as a standard for technical recruiters and employers.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

CodeSignal raised $25M on 12/08/2020

Similar Companies

Sunbit

Sunbit empowers merchants to earn more by offering access to flexible payment plans. Customers can get what they need now and pay-over-time—its a win/win!

Health Care Compliance Strategies (hccs)

Health Care Compliance Strategies (hccs) is a Jericho, NY-based company in the Software and Internet sector.

Adeptive Software

Independently-owned and operated, Adeptive Software develops the powerful ResWare title and escrow production platform. ResWare is a sophisticated, yet flexible solution providing smart and scalable workflow automation, a secure collaboration portal, numerous provider and bank integrations, and so much more enabling clients to be more productive and thus transform their operations. We believe technology is more than a tool, it should help an organization be the best version of itself. With the ResWare platform and Adeptives industry-experienced staff, we help clients automate and innovate for the transactions of today and those of tomorrow.

Kinnami

Hybrid Resilient Data Fabric for the Connected World

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.